Optimizing Heart Failure with Preserved Ejection Fraction after Atrial Fibrillation Ablation. (R-15542)

Heart failure with preserved ejection fraction (HFpEF) is a growing global health concern, accounting for over 50% of all heart failure cases, particularly in aging populations with multiple comorbidities. Atrial fibrillation (AF), the most prevalent arrhythmia in HF, frequently co-occurs with HFpEF, exacerbating symptoms, reducing functional capacity, and increasing hospitalization risk. Despite the significant overlap in pathophysiology between HFpEF and AF, diagnostic challenges lead to frequent underrecognition of HFpEF in AF patients, resulting in suboptimal treatment. This research aims to address these gaps through three objectives: (i) assessing HFpEF prevalence and underdiagnosis in AF using contemporary scoring systems; (ii) refining non-invasive diagnostic strategies by validating clinical, echocardiographic, electro-anatomical, and biomarker-based tools; and (iii) evaluating the impact of optimized guideline-directed medical therapy and comorbidity management on clinical outcomes post-ablation. By improving HFpEF detection and implementing tailored therapeutic strategies, this study aims to enhance patient-centered outcomes, mitigate disease progression, and optimize healthcare resource utilization, ultimately contributing to a more integrated and multidisciplinary approach to heart failure management.

Keywords:heart failure management pathway in AF patients, HFpEF in atrial fibrillation, non-invasive diagnostic strategies for HFpEF

Disciplines:Cardiology